The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s controlled release drug delivery market report forecasts the controlled release drug delivery market size to grow to $92.60 Billion by 2027, with a CAGR (compound annual growth rate) of more than 11%.

Learn More On The Controlled Release Drug Delivery Market Report 2023 – https://www.thebusinessresearchcompany.com/report/controlled-release-drug-delivery-global-market-report

Controlled Release Drug Delivery Market Size Forecast
The global controlled release drug delivery market is expected to grow from $52.93 billion in 2022 to $59.20 billion in 2023 at a compound annual growth rate (CAGR) of 11.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global controlled-release drug delivery market size is expected to reach $92.60 billion in 2027 at a CAGR of 11.8%.

North America held the largest controlled release drug delivery market share.

Key Controlled Release Drug Delivery Market Driver ­– Rise In The Prevalence Of Chronic Diseases
For example, according to a data released by the World Health Organisation (WHO), a Switzerland-based health-specialized institution, 41 million people die each year from chronic diseases, accounting for 74% of all fatalities globally in September 2022. Chronic illnesses claim the lives of 17 million people before the age of 70. Furthermore, low- and middle-income countries account for 77% of chronic illness mortality. These figures are projected to climb further in the future. As a result, the increased prevalence of chronic diseases is propelling the controlled release medication delivery market forward.

Request for A Sample Of The Global Controlled Release Drug Delivery Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9930&type=smp

Key Controlled Release Drug Delivery Market Trend – Technological Advancement
To maintain their market position, major businesses in the controlled-release drug delivery sector are using new technologies. For example, Evonik Industries AG, a German pharmaceutical company, will launch Eudratec Fasteric in October 2020, an oral drug delivery technology that increases gastric resistance and improves intestinal absorption for oral drug products that target sites in the upper small intestine with a narrow absorption window. Furthermore, it can be processed rapidly and efficiently using conventional instruments and is compatible with a wide range of oral dose forms, including multiarticulate, tablets, and capsules.

Controlled Release Drug Delivery Market Segment
1) By Technology: Wurster Technique, Coacervation, Micro Encapsulation, Implants, Transdermal, Targeted Delivery, Other Technologies
2) By Release Mechanism: Polymer Based Systems, Micro Reservoir Partition Controlled Drug Delivery Systems, Feedback Regulated Drug Delivery Systems, Activation-Modulated Drug Delivery Systems, Chemically Activated,
3) By Application: Metered Dose Inhalers, Injectable, Transdermal and Ocular Patches, Other Applications
4) By End User: Hospitals, Clinics, Peronal, Research, Other End Users

Controlled Release Drug Delivery Market Major Players and Strategies
Major players in the controlled release drug delivery market are Johnson And Johnson, Merck And Co. Inc., Alkermes Plc., Coating Place Inc., Corium International Inc., Depomed Inc., Pfizer Inc., Aradigm Corporation, Capsugel, GlaxoSmithKline Plc., Bayer Healthcare LLC, Collegium Pharmaceuticals, GE Healthcare, Adare Pharma Solutions, Allergan Plc., and Novartis AG.

Adare Pharmaceutical Inc., a US-based pharmaceutical firm that supplies advanced pharmaceutical technology, paid an unknown sum to purchase Orbis Biosciences Inc. in May 2020. Adare Pharmaceutical Inc wants to broaden its product offerings by extending its platforms to generate medication particles that may be dosed in oral liquid, intravenous, and otic dosage forms. Orbis Biosciences Inc. is a biotech firm established in the United States that develops controlled-release delivery solutions to increase compliance in the oral drug, medical, chemical, and consumer goods industries.

The Controlled Release Drug Delivery Global Market Report 2023 covers regional data on controlled release drug delivery market size, controlled release drug delivery market trends and drivers, opportunities, strategies, and controlled release drug delivery market competitor analysis. The countries covered in the controlled release drug delivery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

A controlled release drug delivery dosage form is one that dispenses a medicine or treatment in a specific manner. This type of drug delivery continually administers pharmaceuticals or treatments in predictable kinetics for a set period of time.

View More Reports Related To The Controlled Release Drug Delivery Market –
Controlled Release Fertilizer Global Market Report 2023
Controlled Substance Global Market Report 2023
Drug Delivery Devices Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: